28 C
Tuesday, May 28, 2024

Covid: Govt approves Bharat Biotech’s nasal vaccine, to be introduced on CoWIN

Must Read

Batori24 Bureau
Batori24 Bureau
Batori24 is a Vernacular based Assamese news portal based in Guwahati Assam. We are a dedicated news channel covering news and stories across the globe with special reference to Assam, north-east along with National and International news.

Dr. Mansukh Mandaviya, Minister of Health, announced that the Bharat Biotech nasal vaccine has been approved and will be included in the CoWIN app.

“The Indian government has approved the Nasal vaccine. It will first be available in private hospitals as a heterologous booster. It will be included in the Covid vaccination programme beginning today “According to official sources.

According to PTI, Bharat Biotech’s intranasal Covid vaccine will be available in private clinics and will be introduced on CoWIN on Friday evening.


Bharat Biotech, the manufacturer of Covaxin, will roll out its nasal vaccine as a booster dose, providing more options for third or precautionary doses in India.

Also Read: What Is BF.7, The Omicron Sub-Variant Behind COVID Surge In China Now Reported In India

The Nasal vaccine developed by Bharat Biotech will be India’s first such booster dose. It can be given to people over the age of 18. The vaccine’s price will be determined soon, and it will be available in both government and private facilities.

The CoWin portal currently lists Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, Russian Sputink V, and Biological E Ltd’s Corbevax. On September 6, the vaccine manufacturer announced that its iNCOVACC (BBV154) had been approved by the Drugs Controller General of India for Restricted Use in Emergency Situations for people aged 18 and up.

China is seeing an increase in COVID-19 cases as a result of increased patient numbers at several hospitals across the country. Medical resources in China’s capital city, Beijing, are under additional strain as a result of the latest wave. The current increase in COVID cases in China is thought to be caused by the Omicron BF.7 subvariant. India confirmed three cases of Omicron subvariant BF.7 in the country thus far on Wednesday.

Omicron Sub-Variant BF.7 of Covid In India – What Do We Know

According to sources in the Union Health Ministry, four cases of the BF.7 variant of Omicron, which is responsible for the surge in Covid-19 cases in China, have been discovered in India.

While two cases were discovered in Gujarat, one was discovered in Odisha.

Two new BF.7 cases have been identified in Gujarat’s Vadodara and Ahmedabad.

A 61-year-old NRI woman from the Sabhanpura neighbourhood of Vadodara tested positive for the BF.

Covid-19 has seven variants.



Given the growing number of Covid-19 cases reported from China and other countries, the Centre has already requested that states send samples of positive cases for genome sequencing.

What is Omicron Subvariant BF.7 ?

According to a PTI report, BF.7 is a sub-lineage of the Omicron variant BA.5, and has the strongest infection ability because it is highly transmissible, has a shorter incubation period, and has a higher capacity to cause reinfection or infect even those who have been vaccinated.

Omicron Subvariant BF.7 Symptom, Precaution, Treatment

The new variant exhibits upper respiratory infection-like symptoms such as fever, sore throat, runny nose, and cough.

BA., a sub-lineage of the Omicron variant, is the same as BF.7. BA.5.
The subvariant of Omicron BF.7 has the greatest ability to infect.
The Omicron subvariant BF.7 is thought to be extremely transmissible.
The incubation period for the BF.7 subvariant is shorter.
It has a greater ability to reinfect or infect even those who have been vaccinated.

According to reports, Chinese cities are being hit by the highly transmissible Omicron strain, primarily BF.7, which is the main variant spreading in Beijing and contributing to a larger surge of COVID infections in the country. It has already been discovered in several other countries, including the United States, the United Kingdom, and European countries such as Belgium, Germany, France, and Denmark.

“The BF.7’s high transmissibility in China may be attributed to a low level of immunity in the Chinese population from previous infection and possibly vaccination,” an official source told PTI.

- Advertisement -
- Advertisement -

Latest News

Bhupen Borah heads to Jorhat, to face police Inquiry amid Political turmoil

Police in Jorhat have summoned Assam Congress chairman Bhupen Borah to appear before them on January 31 in relation to a case involving the Bharat Jodo Nyay Yatra, which is suspected of deviating from its approved route in the district.
- Advertisement -

More Articles Like This

- Advertisement -